Comparison Study of Doxorubicin Versus Epirubicin-induced Cardiotoxicity in Patients With DLBCL

NCT00854568 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

398

Enrollment

OTHER

Sponsor class

Conditions

Lymphoma

Interventions

DRUG: CEOP regimen
DRUG: CHOP regimen

Sponsor

Fudan University